LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts

Shares of LivaNova Plc LIVN Tuesday climbed along with several other big stocks.

There is high visibility into the company's near-term baseline growth, with potential upside to revenue and earnings from "new product cycles and pipeline optionality," according to Goldman Sachs.

Analyst David Roman initiated coverage of LivaNova with a Buy rating and price target of $65.

The LivaNova Thesis: LivaNova's earnings had been under pressure due to strategic shifts in the company's business and pipeline setbacks. Roman said in the initiation note.

Check out other analyst stock ratings.

With a greater focus on commercial execution, "given the recent transition in corporate strategy," LivaNova could generate consistent results and margin profile improvement, which would make its period of underperformance fade "into the rearview mirror," he added.

From here, LivaNova's base business is poised to generate around 5% revenue growth from "stable-end markets and de novo neuromodulation implants as well as a near-term bolus of growth from an identifiable product cycle upgrade in cardiopulmonary (52% of sales)," the analyst wrote.

Sustained revenue growth, improved mix, and more targeted cost management could drive "outsized EPS growth" of around 14% through 2027, he further stated.

LIVN Price Action: Shares of LivaNova were up 0.6% to $53.53 at the time of publication on Friday.

Read More:

• Medtronic Recalls MiniMed Pump Due To Battery Life Concerns

Image created using artificial intelligence via Midjourney.